Search Results

AUGUSTUS Compares Antithrombetic Therapies in Patients Treated for AF and ACS

September 26, 2019—Insights from the AUGUSTUS ACS trial were published by Stephan Windecker, MD, et al in Circulation simultaneous with Dr.

BIOFLOW-II Results Published for Biotronik's Orsiro SES With Biodegradable Polymer

March 9, 2015—Results of the randomized BIOFLOW-II trial were published online by Stephan Windecker, MD, et al in Circulation: Cardiovascular Interventions.

Editorial Addresses European Industry Proposal to Withdraw Direct Sponsorships of Conference Attendees

November 23, 2015—Patrick W. Serruys, MD, Editor-in-Chief of EuroIntervention; William Wijns, MD, Chairman of PCR; and Stephan Windecker, President of EAPCI, the European Association of Percutaneous Cardiovascular Interventions, announced the expedited publication of their editorial in EuroIntervention, which addresses an upcoming Eucomed vote that will influence sponsorship of continuing medical education (CME). 

Onyx ONE Study Evaluates 1-Month DAPT in High-Bleeding Risk Patients

September 26, 2019—The Cardiovascular Research Foundation (CRF) announced that results from the Onyx One study were presented by Stephan Windecker, MD, at TCT 2019, the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium, which is sponsored by CRF and held September 25–29 in San Francisco, California.

Medtronic Initiates Global Study of 1-Month DAPT After Implantation of Resolute Onyx DES

August 14, 2017—Medtronic announced a global randomized clinical trial that will evaluate 1-month dual antiplatelet therapy (DAPT) in patients who have undergone implantation of the company's Resolute Onyx drug-eluting stent (DES) during percutaneous coronary intervention (PCI).

Enrollment Begins in REMEDEE Trial of OrbusNeich's Combo DES

December 1, 2009—OrbusNeich, Inc. (Fort Lauderdale, FL) announced the initiation of patient enrollment in the REMEDEE (Randomized Evaluation of an Abluminal Sirolimus-Coated Bio-Engineered Stent) clinical trial of the company's Combo bioengineered sirolimus-eluting stent.

Edwards Sapien XT TAVR Device Supported by Postmarket SOURCE XT Registry

May 21, 2013—Edwards Lifesciences (Irvine, CA) announced that 1-year data from the SOURCE XT registry continued to demonstrate positive patient outcomes, including all-cause mortality and complication rates.

Positive 9-Month Results From BIOFLOW-II and 12-Month Results From BIOFLOW-III Presented for Biotronik Orsiro DES

May 30, 2013—Primary endpoint results from the BIOFLOW-II clinical study demonstrating the noninferiority of the Orsiro hybrid drug-eluting stent (Biotronik, Inc.; Lake Oswego, OR) compared to Xience Prime (Abbott, Santa Clara, CA) were presented in a late-breaking clinical trials session at EuroPCR in Paris, France, by Principal Investigator Prof.

One-Year Data Published From Edwards' European Postmarket SOURCE XT Registry

May 4, 2015—The 1-year outcomes from the SOURCE XT registry on the second-generation Sapien XT transcatheter heart valve (Edwards Lifesciences) in patients with severe aortic stenosis were published by Gerhard Schymik, MD, et al in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2015;8:657–669).

Anteris’ DurAVR THV Global Pivotal Trial Receives First European Regulatory Clearance 

October 20, 2025—Anteris Technologies Global Corp. announced it has received regulatory clearance from the Danish Medicines Agency to initiate the global pivotal PARADIGM trial evaluating the company’s DurAVR transcatheter heart valve (THV) in patients with severe calcific aortic stenosis.

CE Mark Approved for 1-Month DAPT Indication for High Bleeding Risk Patients Treated With Medtronic’s Resolute Onyx DES

June 5, 2020—Medtronic announced it has received European CE Mark approval for a 1-month dual antiplatelet therapy (DAPT) indication for high bleeding risk (HBR) patients implanted with the Resolute Onyx drug-eluting stent (DES).

Medtronic's Resolute Integrity DES Approved for New Indications in Europe

May 15, 2012—At the EuroPCR 2012 conference in Paris, Medtronic, Inc. (Minneapolis, MN) announced that the Resolute Integrity coronary drug-eluting stent (DES) system has received European regulatory approval for several new indications: acute coronary syndrome, acute myocardial infarction, unstable angina, total occlusions and chronic total occlusions, and in-stent restenosis.

Abiomed Begins PROTECT IV RCT of Impella in High-Risk PCI

April 15, 2021—Abiomed announced that the first patient has been enrolled in the PROTECT IV study of the company’s Impella device.

Biosensors Announces Large Global Trial of BioMatrix Flex DES

May 18, 2011—Biosensors International Group, Ltd. (Singapore) announced plans for the Global LEADERS (LEADERS II) randomized clinical trial, which involves a head-to-head comparison between two drug-eluting stents (DES).

Medtronic Reports Results From Onyx ONE Clear Study of 1-Month DAPT in High Bleeding-Risk DES Patients

March 30, 2020—Medtronic announced positive results of the Onyx ONE Clear study that evaluated the company's Resolute Onyx drug-eluting stent (DES) in high bleeding-risk (HBR) patients with 1-month dual antiplatelet therapy (DAPT).

European Medical Technology Industry Adopts New Code of Ethical Business Practice

December 2, 2015—MedTech Europe announced that members of the European Diagnostics Manufacturers Association (EDMA) and the European Medical Technology Industry (Eucomed) have approved a new Code of Ethical Business Practice. The new code is part of a continuous effort to set high ethical standards for the medical technology industry across Europe.

COMFORTABLE AMI Data Support Biolimus-Eluting Stents With Biodegradable Polymer in STEMI Patients

August 22, 2012—In the COMFORTABLE AMI trial, investigators sought to compare stents that elute biolimus from a biodegradable polymer versus bare-metal stents for use in primary percutaneous coronary intervention (PCI).

EuroPCR Panel Reviews Advances in Complex Cardiovascular Interventions

May 21, 2014—New technological advances, such as leadless cardiac pacing and the latest generation of transcatheter heart valves, were discussed at a session organized by the European Heart Rhythm Association (EHRA) and the European Association for Percutaneous Cardiovascular Interventions (EAPCI) at EuroPCR 2014 in Paris, France.